The primary sequence of phospholipase-A from bee venom

Crystal structure of bee-venom phospholipase A2: correction.

* SCIENCE (ISSN 0036-8075) is published weekly on Friday, except the last week In December, by the American Association for the Advancement of Science, 1333 H Street, NW, Washington, DC 20005. Second-class postage (publication No. 484460) paid at Washington, DC, and additional mailing offices. Copyright

Bitis gabonica venom. The amino acid sequence of phospholipase A.

Bitis gabonica phospholipase A contains 118 amino acid residues in a single chain and is cross-linked by six disulfide bridges. Cyanogen bromide cleavage, and tryptic and chymotryptic digests provided the necessary overlapping peptides allowing the derivation of the complete amino acid sequence. In its primary structure the enzyme is more closely related to porcine pancreatic phospholipase A th...

Inhibition of beta-bungarotoxin action by bee venom phospholipase A2.

(3-Bungarotoxin ((3-BuTX) induces twitching of innervated frog muscle and subsequently blocks transm itter release from motor nerve endings. These actions of P-BuTX are prevented if the nerve-muscle junctions are pretreated with a low concentration of phospholipase A2 from bee venom. When the Ca2+ in the external fluid is replaced by Sr2+, the phospho­ lipase activity of P-BuTX is negligible an...

Phospholipase B in snake venoms and bee venom.

Bee Venom Phospholipase A2: Yesterday’s Enemy Becomes Today’s Friend

Bee venom therapy has been used to treat immune-related diseases such as arthritis for a long time. Recently, it has revealed that group III secretory phospholipase A2 from bee venom (bee venom group III sPLA2) has in vitro and in vivo immunomodulatory effects. A growing number of reports have demonstrated the therapeutic effects of bee venom group III sPLA2. Notably, new experimental data have...